Elafibranor and GFT505, which act as dual PPARα and PPARδ agonists, have shown a good response in the treatment of non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD) and its associated metabolic syndrome (MetS) [19,20]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.